% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Langen:1010199,
      author       = {Langen, Karl-Josef and Galldiks, Norbert and Mauler, Jörg
                      and Kocher, Martin and Filß, Christian Peter and Stoffels,
                      Gabriele and Régio Brambilla, Cláudia and Stegmayr, Carina
                      and Willuweit, Antje and Worthoff, Wieland Alexander and
                      Shah, Nadim Jon and Lerche, Christoph and Mottaghy, Felix
                      Manuel and Lohmann, Philipp},
      title        = {{H}ybrid {PET}/{MRI} in {C}erebral {G}lioma: {C}urrent
                      {S}tatus and {P}erspectives},
      journal      = {Cancers},
      volume       = {15},
      number       = {14},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {FZJ-2023-03010},
      pages        = {3577 -},
      year         = {2023},
      note         = {„Open access publication funded by the Deutsche
                      Forschungsgemeinschaft (DFG, German Research Foundation) –
                      491111487“},
      abstract     = {Advanced MRI methods and PET using radiolabelled amino
                      acids provide valuable information, in addition to
                      conventional MR imaging, for brain tumour diagnostics. These
                      methods are particularly helpful in challenging situations
                      such as the differentiation of malignant processes from
                      benign lesions, the identification of non-enhancing glioma
                      subregions, the differentiation of tumour progression from
                      treatment-related changes, and the early assessment of
                      responses to anticancer therapy. The debate over which of
                      the methods is preferable in which situation is ongoing, and
                      has been addressed in numerous studies. Currently, most
                      radiology and nuclear medicine departments perform these
                      examinations independently of each other, leading to
                      multiple examinations for the patient. The advent of hybrid
                      PET/MRI allowed a convergence of the methods, but to date
                      simultaneous imaging has reached little relevance in
                      clinical neuro-oncology. This is partly due to the limited
                      availability of hybrid PET/MRI scanners, but is also due to
                      the fact that PET is a second-line examination in brain
                      tumours. PET is only required in equivocal situations, and
                      the spatial co-registration of PET examinations of the brain
                      to previous MRI is possible without disadvantage. A key
                      factor for the benefit of PET/MRI in neuro-oncology is a
                      multimodal approach that provides decisive improvements in
                      the diagnostics of brain tumours compared with a single
                      modality. This review focuses on studies investigating the
                      diagnostic value of combined amino acid PET and 'advanced'
                      MRI in patients with cerebral gliomas. Available studies
                      suggest that the combination of amino acid PET and advanced
                      MRI improves grading and the histomolecular characterisation
                      of newly diagnosed tumours. Few data are available
                      concerning the delineation of tumour extent. A clear
                      additive diagnostic value of amino acid PET and advanced MRI
                      can be achieved regarding the differentiation of tumour
                      recurrence from treatment-related changes. Here, the
                      PET-guided evaluation of advanced MR methods seems to be
                      helpful. In summary, there is growing evidence that a
                      multimodal approach can achieve decisive improvements in the
                      diagnostics of cerebral gliomas, for which hybrid PET/MRI
                      offers optimal conditions.},
      cin          = {INM-3 / INM-4 / INM-11 / JARA-BRAIN},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406 /
                      I:(DE-Juel1)INM-11-20170113 / $I:(DE-82)080010_20140620$},
      pnm          = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5252},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {37509252},
      UT           = {WOS:001035143600001},
      doi          = {10.3390/cancers15143577},
      url          = {https://juser.fz-juelich.de/record/1010199},
}